Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia: A Comprehensive Review  by Kharfan-Dabaja, Mohamed A. et al.
H
P
I
r
a
e
t
(
e
T
l
c
a
s
Biology of Blood and Marrow Transplantation 13:997-1004 (2007)
 2007 American Society for Blood and Marrow Transplantation
1083-8791/07/1309-0001$32.00/0
doi:10.1016/j.bbmt.2007.05.005ematopoietic Cell Transplantation in Acute
romyelocytic Leukemia: A Comprehensive Review
Mohamed A. Kharfan-Dabaja,1 Yasser R. Abou Mourad,2 Hugo F. Fernandez,1 Marcelo C. Pasquini,3
Edgardo S. Santos4
1Division of Blood and Marrow Transplantation, Department of Interdisciplinary Oncology, H. Lee Mofﬁtt Cancer
Center and Research Institute and University of South Florida, Tampa, Florida; 2Leukemia and Bone Marrow
Transplantation Program of British Columbia, Division of Hematology, Vancouver General Hospital, Vancouver,
BC, Canada; 3Division of Neoplastic Diseases and Related Disorders, Medical College of Wisconsin, Milwaukee,
Wisconsin; and 4Division of Hematology-Oncology, Tulane Cancer Center, Tulane University School of Medicine,
New Orleans, Louisiana
Correspondence and reprint requests: Mohamed A. Kharfan-Dabaja, MD, FACP, Division of Blood and Marrow
Transplantation, H. Lee Mofﬁtt Cancer Center/University of South Florida, 12902 Magnolia Drive, WCB-BMT,
Tampa, FL 33612 (e-mail: Kharfama@mofﬁtt.usf.edu).
Received February 5, 2007; accepted May 2, 2007
ABSTRACT
The past three decades have brought major therapeutic advances in the management of acute promyelocytic
leukemia. The current state-of-the-art induction treatment with all-trans retinoic acid in combination with
anthracycline-based chemotherapy results in long-lasting remissions and cure in up to 70% of newly diagnosed
patients. Unfortunately, treatment failure still occurs in one-third of patients. When disease relapses, patients
can achieve subsequent remissions with arsenic trioxide, all-trans retinoic acid with or without chemotherapy,
or other therapies. Patients achieving molecular remissions after salvage therapy are generally considered
candidates for high-dose chemotherapy and autologous hematopoietic cell transplantation as a postconsoli-
dation strategy. On the other hand, patients with evidence of persistent hematologic or molecular disease after
salvage therapy could be offered allogeneic hematopoietic transplantation if a suitable HLA-donor is identified
and the patient’s overall performance and clinical condition are permissible. We hereby provide a compre-
hensive review and analysis of published clinical trials that evaluate the role of hematopoietic cell transplan-
tation across different stages of acute promyelocytic leukemia.
© 2007 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Treatment of acute promyelocytic leukemia (APL)
epresents one of the ﬁrst successes of targeted therapy
gainst cancer [1]. APL is unique from other acute my-
loid leukemias (AML) because of the presence of a
ranslocation involving the retinoic acid receptor-
RAR-) gene on chromosome 17 (q21) and the promy-
locytic leukemia gene (PML) on chromosome 15 (q22).
he resulting PML-RAR- aberrant protein product
eads to arrest of myeloid differentiation and plays a
ritical role in the pathogenesis of the disease. APL is
lso associated with a distinct coagulopathy, which re-
ults in disseminated intravascular coagulation, contrib- fting to signiﬁcant morbidity and mortality [2-4]. The
ntroduction of all-trans retinoic acid (ATRA) has im-
roved remission rates and overall prognosis of APL
1,5]. ATRA also has a beneﬁcial effect on hemostasis,
eading to a relatively rapid resolution of the APL-asso-
iated coagulopathy [6]. Addition of ATRA to conven-
ional chemotherapy results in improved outcomes,
ostly from reduction in relapse rates, compared to
onventional chemotherapy alone [3,4,7,8]. However,
p to 1/3 of patients still relapse after treatment with
TRA plus chemotherapy [8-10]. Arsenic trioxide has
merged as a promising salvage therapy capable of
nducing complete remissions (CR) in patients who
ailed or relapsed after ATRA-based therapy [11-13].
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M. A. Kharfan-Dabaja et al.998In general, patients with relapsed APL who
chieve a second molecular remission (CR2m) with
rsenic trioxide, or other therapies, are offered high-
ose chemotherapy (HDCT) with autologous hema-
opoietic cell transplantation (auto-HCT), or alloge-
eic (allo-HCT) if a suitable HLA matched donor is
vailable. We provide a comprehensive review of the
ole of HCT, autologous and allogeneic, in patients
ith APL.
UTOLOGOUS HCT IN APL
n First Complete Remission (CR1)
Because APL is highly curable with ATRA plus
nthracycline combinations, HDCT and auto-HCT is
ot routinely recommended for patients in CR1 [14,15].
onetheless, it is important to identify patients who are
t high-risk for relapse after standard therapy. A joint
tudy by the GIMEMA and PETHEMA cooperative
roups stratiﬁed prognostic groups in newly diag-
osed APL patients based on the initial white blood
ell (WBC) and platelet counts into 3 risk groups: (1)
ow (WBC 10  109/L and platelet 40  109/L);
2) intermediate (WBC 10  109/L and platelet
40 109/L); and (3) high-risk (WBC10 109/L)
10]. In a multivariate analysis, increased WBC
10  109/L) was shown to be associated with a
igher incidence of relapse in the central nervous
ystem, and hence a poor prognosis [16]. But whether
uto-HCT may offer a therapeutic advantage in these
igh-risk cases is not known.
The LPA99 study conducted by the PETHEMA
roup showed that patients with intermediate- and
igh-risk group disease achieve longer disease-free
urvival (DFS) and overall survival (OS) by increasing
he dose of anthracyclines and extending ATRA into
onsolidation cycles [17]. Conversely, preliminary re-
ults of the North American Intergroup C9710
CALGB, ECOG, SWOG, COG, NCIC-CTG) pre-
ented at the 2006 annual meeting of the American
ociety of Hematology (ASH) suggests that patients
ith a WBC 10  109/L at diagnosis may require
lternative therapeutic modalities to decrease early
elapse rates [18]. One such modality to be consid-
red, yet still unproved in this setting, is HDCT and
uto-HCT.
A study by Ottaviani et al. [19] reported 16 pa-
ients with APL who received auto-HCT as consoli-
ation therapy after achieving CR1. Thirteen (81%)
ere transplanted in CR1 and 1 (6%) in ﬁrst partial
emission (PR1). All patients received busulfan and
yclophosphamide (BU-CY) as conditioning regimen.
atients were analyzed for the presence of PML-
AR- fusion gene by reverse transcriptase polymer-
se chain reaction (RT-PCR) before auto-HCT, and
uring posttransplant follow-up as well. All patients lransplanted in CR1 were in cytogenetic remission
CyCR), but only 11 (85%) of 13 were in molecular
emission (CRm) in bone marrow (BM) samples eval-
ated prior to transplantation. The median duration
f remission for patients transplanted in CR1 was 55
range: 7-71) months. Eleven patients in CRm at the
ime of auto-HCT maintained molecular remissions.
he outcome for 3 patients who did not achieve CRm
efore transplantation was as follows: 2 patients re-
apsed early after autograft and died of progressive
isease; the other attained and remained in CRm for
1 months after auto-HCT. In the latter case, har-
ested BM cells were purged prior to transplantation.
his study shows that persistent molecular disease
rior to auto-HCT is highly predictive of relapse in
atients undergoing auto-HCT [19]. It also shows that
uto-HCT might be a treatment alternative, to pro-
onged maintenance therapy, in patients in ﬁrst CRm
CR1m), and suggest that purging is feasible in patients
ith molecular disease prior to transplantation. The
tudy is limited by the fact that the sample size is rela-
ively small.
In a retrospective study, Mandelli et al. [20] re-
orted outcomes of 362 patients with APL who re-
eived HCT (auto-HCT: 187, allo-HCT: 175). Most
f the patients (N  129) who received an auto-HCT
ere transplanted in CR1. Transplant-related mortal-
ty (TRM) was higher in patients undergoing allo-
rafts (42% versus 19%). The 7-years leukemia-free
urvival (LFS) in patients transplanted in CR1 were
8% and 42% after auto- and allo-HCT, respectively
20]. When evaluating patients transplanted in CR2,
he 4-year LFS was 31% and 22% after auto- and
llo-HCT, respectively. These results suggest that
ransplanting at an earlier stage of disease may be
eneﬁcial; however, several limitations need to be
onsidered when interpreting the data: (1) the study
ncluded children (auto: 18% [34/187]; allo: 20% [35/
75]); (2) the study was retrospective and did not take
nto account the effect of initial ATRA therapy (versus
o ATRA) on posttransplant outcome; and (3) the
RM for auto-HCT recipients is higher than what
as been seen in more recent studies ranging from 0%
o 9% (Table 1). Recent improvements in TRM are
robably explained by better antimicrobial prophy-
axis and monitoring of posttransplant toxicities.
The evidence to recommend auto-HCT in pa-
ients in CR1 is limited. Whether patients with WBC
10  109/L), who are at higher risk for developing
entral nervous system (CNS) relapses, may beneﬁt
rom HDCT, and autograft in CR1 is not known.
lso, the role of auto-HCT as ﬁrst-line consolidative
herapy is not established for patients with transloca-
ions such as t (11;17 expressing PLZF/RAR-),
mong others, known to be resistant to ATRA therapy
21,22]. Patients with hematologic or molecular re-
apses after auto-HCT are appropriate candidates for
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Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia 999einduction therapy with arsenic trioxide based on
any reported trials [13,14,23,24]. Molecular surveil-
ance of the disease could detect early molecular re-
apse and allow for earlier intervention before overt
linical relapse ensues.
n Second or Further CRs (>CR2)
Auto-HCT plays an important therapeutic role in
atients with APL inCR2. Data from the Center for
nternational Blood and Marrow Transplant Research
CIBMTR) demonstrate that the majority of patients
ith APL receive HCT in second or subsequent re-
issions (CR2). The 3-year probabilities of OS for
atients with APL in CR2 are 73% (4%) and 61%
3%) after auto-HCT and allo-HCT, respectively
Figures 1 and 2).
A trial by Meloni et al. [25] reported the outcome
f 15 relapsed APL patients who received an auto-
CT in CR2 with unpurged BM cells. Only 2 pa-
ients had been treated with ATRA-based regimens
uring initial diagnosis, and all had received 3 cycles
f consolidation chemotherapy. The duration of CR1
anged from 6 to 40 months. CR2 was reinduced with
TRA in all patients. Twelve patients received con-
olidation therapy with cytarabine and mitoxantrone.
he median time from attaining CR2 to undergoing
able 1. Selected Studies Evaluating Autologous HCT in Relapsed APL
Authors/Reference N
Age
(median)
Disease Status
at Transplant
Con
Re
andelli et al. (20) 187* 30 CR1: 129
CR2: 58
TBI-b
Not-T
akatsuki, et al. (31) 6 — CR1: 6 BU-A
eloni, et al. (25) 15 38 CR2: 15
PCR: 7
PCR: 8
BAVC
BU-C
errant, et al. (32) 36 — CR1: 36
oman, et al. (33) 10 47 CR1: 8
CR2: 1
PR: 1
BU-C
CY-TB
CY-FT
o Coco, et al. (34) 8 40 CR2: 8 BAVC
BU-C
homas, et al. (27) 22 — CR2: 22 CY-TB
BU-ba
homas, et al. (28) 9 — CR2: 9
ttaviani, et al. (19) 16 30 CR1: 13
PR1: 1
CR2: 1
CR3: 1
BU-C
errara, et al (35) 6 38 CR2: 6 Ida-BU
BAVC
e Botton, et al. (30) 50 45 CR2: 50 CY-TB
BU-C
BU-M
CY-M
RM indicates transplant related mortality; DFS, disease-free surv
total-body irradiation; CY-TBI, cyclophosphamide and total-bo
ARA-C, m-AMSA, VP-16; LFS, leukemia-free survival; BU-ME
: 34 patients were children.utograft was 2 (range: 2-7) months. Seven (47%) aatients had evidence of persistent molecular disease
y PCR (PCR) and 8 (53%) were in CR2m (PCR).
ll 7 patients who underwent auto-HCT with PCR
isease relapsed at a median of 5 (range: 2-9) months
fter transplantation. Six (75%) of 8 patients with
CR-negative disease remained in molecular remis-
ion at a median of 28 (range: 15-60) months after
ransplantation. One patient with PCR-negative dis-
ase relapsed at 10 months after auto-HCT, and 1
eveloped a secondary leukemia. This study suggests
hat patients with persistent molecular disease
PCR) should not be offered auto-HCT. A fol-
ow-up of this study was not able to reproduce previ-
us results [26]. Interestingly, all patients in the sec-
nd group (N  9) had received ATRA-containing
reatments at presentation, compared to only 2 of 7 in
he ﬁrst cohort, raising questions whether relapse after
TRA-based therapy at presentation is representative
f a more aggressive disease, and whether these patients
ould have beneﬁted from arsenic trioxide, or other
alvage therapy prior to undergoing auto-HCT [26].
A study published by Thomas et al. [27] reported
utcome on 50 patients with APL in ﬁrst relapse,
einduced with ATRA and subsequently treated with
equential chemotherapy with etoposide, mitox-
ntrone, and cytarabine. Forty-ﬁve (90%) patients
g
TRM DFS OS
02 18% (CR1)
23% (CR2)
48% 7-years LFS (CR1)
31% 7-years LFS (CR2)
—
16 0% 67% —
0% — 40% at a median of
32 months from
CR2
— 70% 3-years LFS 83% at 3-years
0% 90% 90% median
survival 41
months
0% 75% DFS at 9.5 months —
9% 77% at 3-years 79% at 3-years
0% 100% at 2-years 100% at 2-years
0% Median duration of
CR1: 55 months
Median survival
59.5 months
0% 83% at 36 months —
6% 61% EFS at 7 years 60% at 7-years
S, overall survival; TBI, total-body irradiation; FTBI, fractionated
diation; BU-CY, busulfan and cyclophosphamide; BAVC, BCNU,
ulfan and melphalan; CY-MEL, cyclophosphamide and melphalan.ditionin
gimens
ased: 1
BI: 85
ra-C-VP
: 14
Y: 1
—
Y: 2
I: 2
BI: 6
: 6
Y: 2
I: 16
sed: 6
—
Y: 16
: 4
: 2
I: 28
Y: 17
EL: 4
EL: 1
ival; O
dy irra
L, buschieved CR2, and 5 (10%) patients died as a result of
i
(
m
m
a
m
w
p
1
t
t
ﬁ
v
2
m
d
O
r
t
b
d
t
s
l
t
a
2
a
m
d
a
p
B
F
t
r ommi
F
t
r
M. A. Kharfan-Dabaja et al.1000nfections. Twenty-two patients received auto-HCT
PBSC: 17; bone marrow (BM): 5). The most com-
on conditioning regimen (73%) was cyclophospha-
ide plus total-body irradiation (TBI). Following
uto-HCT, 8 of 9 patients had ongoing CRm at a
edian of 10 (range: 4-28) months. The 3-year DFS
as 77%. One patient with PCR disease after trans-
lantation died of relapsed disease. Interestingly, 9 of
7 patients who received auto-HCT had longer dura-
ion of remission in CR2 compared to the duration of
heir CR1 at the time the authors published their
ndings. Also, presence of molecular disease in har-
ested hematopoietic cells was evaluated in 6 patients:
patients were negative for PML-RAR- rearrange-
ent, whereas the remaining 4 had molecular evi-
ence of disease in at least 1 of the harvested samples.
ne of those 4 patients died as a result of regimen-
igure 1. Survival after autologous transplants performed from
ransplantation. The data presented are preliminary, and were obtain
eviewed by the CIBMTR Advisory or Acute Leukemia Working C
igure 2. Survival after HLA- matched sibling allogeneic transp
ransplantation. The data presented are preliminary and were obtain
eviewed by the CIBMTR Advisory or Acute Leukemia Working Commielated toxicity, and 2 achieved a longer CR2 than
heir initial CR1. This suggests that auto-HCT could
e offered to patients with relapsed APL, even when
isease is detected on harvested cells [27]. Recently,
he same group reported their experience using ar-
enic trioxide as remission-induction therapy for re-
apsed APL [28]. Twenty-four (86%) of 28 consecu-
ive patients with relapsed APL were treated with
rsenic trioxide and achieved CR2. Thirteen (54%) of
4 patients underwent transplantation (auto: 9, allo: 4)
nd all were alive and without relapse (2-year leuke-
ia-free survival [LFS] and OS rates of 100%). This
ata supports a sequential approach of arsenic trioxide
s a “bridge strategy” to auto-HCT.
At the 2000 ASH meeting, Sanz et al. [29] re-
orted the results of a survey from the European
lood and Marrow Transplant (EBMT) Group for
to 2004 for acute promyelocytic leukemia by disease status at
the Statistical Center of the CIBMTR. The analysis has not been
ttee, but permission was granted for this publication.
994-2004 for acute promyelocytic leukemia by disease status at
the Statistical Center of the CIBMTR. The analysis has not been1994
ed fromlants 1
ed fromttee, but permission was granted for this publication.
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Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia 1001atients with APL transplanted with auto- or allo-
CT in the era of ATRA. A total of 278 patients
auto:151; allo:127) were transplanted in CR2.
RM was worse in the allo-HCT group (33%  9%
ersus 25%  12%). Nevertheless, the TRM in the
uto-HCT group is higher than reported in more
ecent trials (Table 1). The 6-year LFS estimates (in
atients CR2) were better after allo-HCT (57% 
0% versus 45%  10%).
A retrospective analysis from the European APL
roup by de Botton et al. [30] reported outcome of 50
atients with APL who received HDCT and autograft
n CR2. The median time from achieving CR2 to
ndergoing auto-HCT was 112 (range: 82-137) days.
lower TRM of 6% was noted. The 7-year event-free
urvival (EFS) and OS were 61% and 60%, respec-
ively. When analysis was limited to patients in
R2m, the 7-year EFS and OS improved to 77% and
5%, respectively. These ﬁndings are consistent with
he reported literature, which support a beneﬁcial role
or auto-HCT in patients with relapsed APL who
nter into CR2m after salvage chemotherapy. These
nd other studies are summarized in Table 1 [25-35].
These data support auto-HCT for patients who
chieve CR2m after salvage therapy for APL. For
atients with persistent molecular disease after rein-
uction therapy the risk of relapse is obviously higher,
nd salvage strategies such as arsenic trioxide aiming
t inducing molecular remissions must be considered
rior to proceeding with auto-HCT. Patients who do
ot achieve molecular remissions with arsenic trioxide
ould be offered an allo-HCT if a suitable HLA-
atched donor is identiﬁed.
AINTENANCE THERAPY AFTER AUTO-HCT: IS
HERE A ROLE?
The beneﬁt of maintenance therapy in APL after
rst induction/consolidation has been shown in 2 ran-
omized clinical trials. The North American Inter-
roup showed that maintenance therapy with ATRA
mproves relapse-free survival (RFS) when compared
o absence of maintenance [34,36]. Similarly, the
PL-93 protocol showed a signiﬁcantly lower relapse
ate in all 3 groups receiving maintenance therapy
29% for ATRA alone, 24% in chemotherapy alone,
nd 13% for the ATRA plus chemotherapy combina-
ion) in comparison to the group that did not receive
ny maintenance therapy (39%) [37]. The beneﬁts
f maintenance therapy in patients with APL who
chieve CRm after induction and consolidation treat-
ent have been questioned in 2 studies [38,39]. Anec-
otal cases in pediatric patients undergoing auto-HCT
ave reported that ATRA may successfully salvage APL
atients with residual disease posttransplant [40].There are no randomized controlled trials evalu- rting the role of maintenance therapy for patients who
nter into, or maintain, CR2m after auto-HCT. Most
atients with APL transplanted in CR2m maintain
heir molecular remissions. So, for the time being,
aintenance therapy after auto-HCT should be con-
idered within the context of clinical trials.
LLOGENEIC HCT IN RELAPSED APL
The efﬁcacy of auto- versus allo-HCT in relapsed
PL has not been compared in randomized controlled
tudies. Allo-HCT is generally reserved for patients
ith good performance status and optimal organ func-
ion for whom a suitable HLA-matched donor is avail-
ble. Mandelli et al. [20] evaluated 175 patients with
elapsed APL who underwent allo-HCT. Forty-ﬁve
ercent of patients received TBI-based conditioning
egimens. Eighty-one percent and 19% were trans-
lanted in CR1 and CR2, respectively. For patients
ransplanted in CR1, TRM was 42%, and the 7-year
FS was 42%  6%. Outcome of allo-HCT trans-
lants in CR2 showed a TRM of 40% and 4-year LFS
f 22%  8%. The relatively high TRM is particu-
arly concerning; however, it is important to consider
hat approximately half of the patients in this trial re-
eived TBI-based myeloablative regimens. At present,
ata on the efﬁcacy of reduced intensity conditioning
RIC) regimens for APL is lacking.
Lo-Coco et al. [41] evaluated the outcome of 17
onsecutive patients, with a median age of 31 years,
ho underwent HLA-sibling matched allo-HCT.
he majority of patients (82%) were transplanted in
R2. Conditioning regimens included BU-CY: 9,
BI-VP16: 7, and Idarubicin-BUCY: 1. Cyclosporine
nd methotrexate was the most commonly used regi-
en for GVHD prophylaxis (65%). BM (71%) was
he most common source of stem cells. Eleven (65%)
atients were in CRm (PCR) pretransplant. TRM
as 32%. At a median follow-up of 50 months, 7
41%) patients remained alive in CRm. The 10-year
ctuarial probability of OS, DFS, and relapse rate
ere 53%, 46%, and 33%, respectively. All 6 patients
ith PCR disease converted to PCR. This study
upports a role for allo-HCT as a valid option for
dvanced APL, particularly in those with persistent
olecular disease prior to transplantation. The re-
ponse may be inﬂuenced by a graft-versus-leukemia
GVL) effect. The authors suggest that lowering the
ntensity of conditioning regimens could reduce TRM
hile preserving the beneﬁcial GVL effect. In another
tudy by de Botton et al. [30] in 23 patients (median
ge; 33 years) who received an allo-HCT (HLA-
atched sibling; 18; unrelated donor: 5) after a me-
ian time of 80.5 days from achieving CR2, TRM was
9%, and 7-year RFS and OS were 92% and 52%,
espectively.
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M. A. Kharfan-Dabaja et al.1002These studies suggest that allo-HCT is a feasible
rocedure that results in few relapses, but at the ex-
ense of increased TRM. The high TRM could be
xplained in part by the resulting toxicity from using
ighly myeloablative regimens such as CY-TBI or
UCY [20,30,33]. RIC regimens could potentially
ecrease the TRM while preserving a GVL effect;
nd such regimens may be reasonable to consider
hen treating patients with persistent disease (he-
atologic or molecular) who have suitable HLA
onors. These and other studies are evaluated in
able 2 [20,27,30,32,33,42].
HERAPY-RELATED MYELODYSPLASTIC SYNDROMES
MDS)/ACUTE MYELOGENOUS LEUKEMIA (AML)
FTER TREATMENT OF APL
The development of therapy-related MDS/AML
t-MDS/AML) with clonal changes different from the
nitial APL clone is a relatively rare event. Chromo-
ome abnormalities that are usually caused by alkylat-
ng chemotherapy can also be observed after therapy
ith anthracyclines [42-44]. Latagliata et al. [45] re-
orted 5 (6.5%) cases of t-MDS/AML in 77 patients
ith APL at different stages of disease. All patients
eceived anthracycline-based chemotherapy. Three
atients were in CR1 and 2 inCR2 after HDCT and
uto-HCT. Aberrations of chromosomes 5 or 7 were
bserved in 2 patients (1 after auto-HCT and 1 in
R1), and median time to develop t-MDS/AML was
6 (range: 24-48) months from initial diagnosis of
PL. A larger analysis by the European APL group
46] reported 6 (0.97%) cases of t-MDS in 617 pa-
ients who entered CR with ATRA plus chemotherapy
able 2. Selected Studies Evaluating Allogeneic HCT in Relapsed APL
Studies/
References N
Age
(median)
Disease Status
at Transplant
Conditioni
Regimen
andelli, et al.
(20)
175* 25 CR1: 142
CR2: 33
TBI-based:
Non-TBI: 9
errant, et al.
(32) 44 — CR1: 44 —
oman, et al.
(33)
10 32 CR1: 8
CR2: 1
2nd relapse: 1
CY-TBI
homas, et al.
(27) 11 —§ CR2: 11 CY-TBI
o-Coco, et al.
(42)
17 31 CR1: 2
CR2: 14
CR3: 1
BU-CY: 9
VP16-TBI:
Ida-BU-CY
e Botton, et al.
(30)
23 33 CR2: 23 CY-TBI: 17
BU-CY: 6
RM indicates transplant-related mortality; LFS, leukemia-free s
irradiation; CY-TBI, cyclophosphamide and total-body irradiat
methotrexate.
: 35 patients were children.
: age of allograft recipients 55 years, median not reported.N  579) or chemotherapy alone (N  38). The aedian age at the time of diagnosis of t-MDS was 59.5
range: 57-76) years and the median time from initial
iagnosis of APL to development of t-MDS was 46.5
range: 13-74) months. Other series have suggested a
% incidence of t-MDS/AML while in ﬁrst CR [47].
hese suggest that t-MDS/AML can occur after an-
hracycline-based therapy for APL, even in the ab-
ence of alkylating agents. Although the incidence of
-MDS/AML is relatively low (0.97% to 6.5%), it is a
erious complication in patients with a potentially
urable disease like APL.
ISCUSSION AND RECOMMENDATIONS
Therapy for APL represents one of the ﬁrst suc-
esses of targeted therapies against cancer. Remark-
ble improvement in outcome has occurred since the
ntroduction of ATRA to the therapeutic armamen-
arium of APL. However, up to 30% of the patients
till fail ATRA-based therapy and require alternative
reatments such as transplantation, autologous or al-
ogeneic, to achieve andmaintain hematologic and pref-
rably molecular remissions.
There are no randomized trials to date that com-
are auto-HCT, or allo-HCT, versus postconsolida-
ion maintenance treatments in patients who enter
R1. But, because 70% of patients are cured with
TRA-based therapy, HCT is generally not offered to
atients in CR1. Allo-HCT is not indicated for APL
atients in CR1 because of the high TRM.
It is standard practice to offer auto-HCT for re-
apsed APL patients who achieve molecular remission
CR2m). Those with relapsed APL who do not
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Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia 1003uch as arsenic trioxide or other salvage therapies are
andidates for allo-HCT if a suitable HLA-matched
onor (sibling or unrelated donors) is identiﬁed and
he patient’s overall performance and clinical condi-
ion are permissible. If allo-HCT is contraindicated,
nrollment in phase I/II clinical trials should be con-
idered. Factors such as molecular status of the disease
t time of transplantation (PCR versus PCR),
vailability of suitable HLA-matched donor, and pa-
ient’s overall performance status should be considered
hen discussing transplantation options with patients
ith APL.
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